Resource constraints, high costs of therapy, and rising national medical expenditures remain interlocked with clinical aspects of healthcare in the United States. 1, 2 In this context, the American College of Cardiology and American Heart Association (ACC/AHA) recently published a rigorous framework to guide integration of economic data into clinical guidelines. 3 These guidelines significantly advance the frameworks that other professional societies have proposed to integrate economic evidence, but they also introduce new challenges. In particular, there is uncertainty about how to incorporate economic information into clinical guidelines, disseminate this guidance to clinicians and influence clinical practice, and determine which economic evidence is of sufficiently high quality to be worth integrating versus which is of lower quality. Regarding the third point, there is empirical cause for concern, because some disease-specific economic reviews report a high prevalence of low quality studies. 4 In this study, we systematically reviewed the quality of economic evaluations/cost-effectiveness analyses (CEAs) pertaining to clinical trials cited in the 2012 ACC/AHA guideline for the diagnosis and management of patients with stable ischemic heart disease, a condition that affects over 15 million adults in the United States. 5, 6 We chose this guideline for our analysis because it has substantial influence on clinical care. In our review, we focus on economic evaluations of randomized controlled trials (RCTs) because this study design represents the highest level of evidence for comparative health effectiveness and therefore should also represent the highest level of evidence for economic evaluations. 7, 8 
Methods

Identification of Randomized Comparison Studies
We reviewed all 1,266 citations in the "2012 ACCF/ AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease." 5 Titles and abstracts of each citation were analyzed to determine whether they contained the word "random," as a flag for whether they were based on randomized controlled trial data. These studies were then selected for full-text review to confirm that they were RCTs. Meta-analyses of multiple randomized studies were excluded.
We then searched PubMed (which includes the MEDLINE database and other sources) and Scopus from inception until March 1, 2015 for English-language articles that were economic evaluations of the randomized controlled trials. As search terms, we used the first author, last author, and/or trial name of the randomized controlled trial, in combination with the Medical Subject Headings cost and economics. If no authors were listed, the study group conducting the trial was listed as the author. If the search yielded greater than 50 search results, the Medical Subject Heading cardiovascular diseases was added to the search terms. If no economic evaluations were found, a Scopus search was performed of all articles citing the referenced RCT containing the term "cost" or "economic" in the title.
Study Selection and Data Extraction
Two investigators (E.S. and D.F.), working independently, in duplicate, identified studies eligible for further review after screening titles or abstracts. Studies then underwent full-text retrieval and data extraction if authors reported using cost and efficacy data from the referenced RCT. Using a standardized protocol and reporting form, data were extracted by two investigators (E.S. and J.L) on the following characteristics: (1) identifying information (first author, journal, country, institution, publication year); (2) parent RCT information as reported in the cost-effectiveness analysis (population characteristics, intervention and control type); (3) economic evaluation characteristics (outcome type, intervention and control costs, outcome value, analysis perspective); and (4) study quality using the Quality of Health Economic Studies (QHES) instrument. 9 Disagreements between reviewers were resolved through discussion. All economic outcomes were converted to 2016 US dollars using historical exchange rates and CPI inflation rates.
10,11
Quality Assessment of Economic Evaluations
Study quality was evaluated using the QHES instrument, a 16-item questionnaire with numerical points to tabulate a quantitative assessment of quality ( Figure 1) . 9 Studies were categorized as high (≥75 points) or low quality (b75 points) based on their score. This threshold was used in a prior study of the quality of economic evaluations. 9, [12] [13] [14] [15] [16] [17] In addition, we performed a detailed methodological assessment of a random subset of high-quality studies (limited to those with a score exceeding the mean QHES score) to identify methodological issues not addressed by the QHES.
Statistical Analysis
The primary outcome was study quality. We also examined the association between study quality and study characteristics. Parent RCT patient characteristics were summarized and descriptive data analysis was performed on study characteristics. Association between low quality scores and study characteristics was assessed using Fisher's exact t-test and Spearman's rank correlation coefficient. All analyses were performed using Stata (version 14, College Station, TX).
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Results
Literature Search
Of the 1,266 articles referenced in the 2012 ACCF/ AHA/ACP/AATS/PCNA/SCAI/STS guidelines, 219 were RCTs. Of these RCTs, we identified economic evaluations for 86, including 14 RCTs that were associated with two economic studies, for a total of 100 economic analyses. Of these analyses, 16 were excluded because they reported only cost data without a health outcome measure, and 7 were excluded because intervention cost and/or efficacy data were not attributable to a single RCT. Seventy-seven papers met inclusion criteria and were selected for data extraction (Figure 2 ). The economic evaluations included in this quality assessment and their parent RCTs are shown in Table I .
Reported Parent Clinical Trial Characteristics
The characteristics of these economic evaluations are summarized in Table II 
Economic Evaluation Characteristics
The most commonly reported primary outcome in the economic evaluations was Cost/Quality-adjusted life-year (QALY) (39.0%), followed by Cost/LYG (33.8%), Cost/ Event Prevented (14.3%), and Cost/Event free year (5.2%); other types of outcomes comprised 9.1% of studies. A social perspective was used in 22.1% of analyses and a third-party payer perspective was used in 42.9% of studies, 20.8% of studies did not report a perspective. One-third (33.8%) used a Markov Model to estimate cost-effectiveness. The majority (72.7%) of economic evaluations received study funding from a private source or a partially private (mixed public and private) source (11.7%), whereas only 10.4% of studies received exclusively public financing. Four studies (5.2%) did not report their funding source. No studies addressed infrastructure and/or investment costs associated with intervention implementation.
Study Quality
The mean quality score was 81 points out of 100, with the lowest score being 59 and the highest 97 (median 83, interquartile range 74-90). Nearly one-third (23/77 studies; 29.8%) of studies were of low quality. Study characteristics associated with lower study quality included not reporting the study perspective (pb0.001) and reporting a non-standard outcome (p=0.021; nonstandard health outcomes were outcomes other than lifeyears, quality-adjusted-life-years, and adverse events prevented). More recent year of publication was associated with higher study quality (p=0.045). When QHES score was treated as continuous rather than dichotomous (high vs low quality), these characteristics remained significant, and other characteristics, including reporting cost-perevent-free-year (p=0.048) and median population size (p= 0.018), were also significant. We identified five of sixteen QHES questions that were significantly associated with study quality. Specifically, 83.3% of high quality studies and 17.4% of low quality studies addressed handling of uncertainty (question 5) (pb0.001), 88.9% of high quality studies and 56.5% of low quality studies performed incremental analysis between alternatives for resources and costs (question 6) (p= 0.003), 87.0% of high quality studies and 43.5% of low quality studies had an appropriate analytic time horizon (question 8) (pb0.001), 87.0% of high quality studies and 52.2% of low quality studies had clearly stated methods (question 12) (p=0.002), and 87.0% of high quality studies and 52.2% of low quality studies stated main assumptions and limitations (question 13) (p=0.002) (Table III) . While the quality score components are used to compute the QHES score and are thus endogenous, this analysis demonstrates which components contribute most to variability between high quality versus low quality scores.
Results of our detailed mythological assessment of a random subset of high-quality studies with a QHES score exceeding the mean are shown in Table IV . This table summarizes methodological domains that are relevant to the validity of economic evaluations but are not addressed with the QHES instrument.
Discussion
We found that fewer than half of the RCTs cited in the 2012 ACC/AHA guidelines on stable ischemic heart disease were associated with an economic evaluation. Of these economic evaluations, nearly one-third (29.9%) met criteria for low-quality. Over time, quality has improved. However, many important elements were not routinely reported, including sex and race/ethnicity distribution of participants in the parent trial from which measures of cost and health effects were estimated (though older white males comprised the majority of the population when these characteristics were reported). In addition, economic evaluations were overwhelmingly funded by private sources, which may raise concerns about sponsor bias. 18 Even among high-quality studies, our detailed analysis of study methods identified methodological domains not addressed by the QHES instrument that are relevant to the validity of an economic evaluation. Together, these findings suggest that economic data can be feasibly incorporated into the 2012 ACC/AHA guidelines-and perhaps other ACC/AHA guidelines-but researchers should exercise caution because of the high proportion of low quality studies, and expert review of "high-quality" studies to examine methodological domains unaddressed by the QHES is necessary. This type of review requires both clinical and quantitative expertise. Furthermore, because the ACC/ AHA has generally been more systematic in its integration of scientific evidence compared to other professional societies, it is likely that low quality evidence may be a larger problem within the cost-effectiveness literature of other health conditions. In fact, prior economic reviews suggest this to be the case. 4, 19, 20 The overall quality of the cardiovascular studies found in this analysis is higher than found in other topical areas including a study of economic analyses in digestive diseases, where Spiegel et al found less than one-third of studies met the QHES criteria for a high quality study. 4 Similarly, in an analysis of CEAs of surgical procedures, Kruper et al. reported that more than three-fourths of studies did not meet criteria for high compliance with analysis criteria. 19 Methodological issues have led to low quality in CEAs of anti-psychotics 20 and other RCT-based economic evaluations. 21 Additionally, in a study of CEAs of cardiac rehabilitation RCTs, Papadakis et al. found more than half of studies were missing essential components of a high quality CEA. 22 Another area of uncertainty is the extent to which guideline developers can distinguish higher quality from lower quality economic studies without applying formal evaluation tools, such as the QHES. Many clinician reviewers may not have training in economic methods. NOTE: Outcome value based on the longest time horizon outcome reported by authors; Dominant represents an intervention that is both less costly and more effective than its comparator ⁎ Cost-effectiveness ratio reflects the finding that intervention was less effective but also less costly than comparator
We believe that there are important implications of limited sex and race/ethnicity diversity of parent RCTs in the context of economic evaluations because of the wide gaps between characteristics of patients enrolling in trials and those of the populations targeted for intervention outside of trials. [23] [24] [25] Of the economic evaluations that reported sex and race, the diversity and representativeness of the populations was limited with the study population primarily consisting of white males. If treatment heterogeneity by sex or race/ethnicity is present, the estimated CE ratio from an economic evaluation can differ from the CE ratio that would be observed in the target population. 7, 8 In fact, depending upon the degree to which trial and target populations differ along this characteristic and the magnitude of the treatment heterogeneity it introduces, the costeffectiveness ratio could vary substantially. This poses an immediate challenge to the integration of economic analyses in physician specialty society guidelines and health policy.
The QHES instrument measures aspects of economic evaluations that are readily identifiable but does not probe equally if not more important methodological components that are more difficult to dissect. This issue is part of the rationale for the detailed methodological assessment reported in Table IV . Potential methodological issues include overly optimistic assumptions about treatment duration or application of clinically inappropriate RCT data (i.e., RCT may target a population that is meaningful different-which is to say that the intervention effect differs-from the population incorporated in an economic evaluation). Potential strategies for attenuating these risks include more detailed checklists that target "missing" methodological domains (such as those highlighted in Table IV) , peer review by individuals with both clinical and economic expertise (in our experience, reviewers usually have expertise in one domain or the other, but rarely both), or formal certification requirements for authors of economic evaluations, with certification used as a proxy for adherence to high methodological standards.
The ease with which results of economic evaluations can be compared may also influence their utility for policymaking. We found substantial heterogeneity in methodological characteristics of the economic evaluations included in our review. Nearly a dozen outcome measures were reported between the CEAs, and no single primary outcome was represented in a majority of the CEAs. Similarly, a clear CEA perspective is necessary for the appropriate incorporation of CEAs into policy decision making. The analysis perspective was not reported in over one-fifth of CEAs and, in a number of instances, the stated perspective differed from the perspective implied by cost elements reported in the analyses. In addition to improving the quality of individual studies, more attention is needed on interstudy comparability. Improved comparability may arise organically as individual study quality rises.
Addressing uncertainty through statistical and sensitivity analyses, as well as assessing cost-effectiveness over sufficiently long time-horizon, are two key elements addressed in the 2016 Panel on Cost-Effectiveness in Health and Medicine guidelines for reporting costeffectiveness. 26 Two-fifths of the economic evaluations did not address uncertainty, and more than a quarter of studies used an insufficient time-horizon. While there were significant differences between high and low quality studies in addressing uncertainty and using appropriate time horizons for analyses, the overall low rate of their use is noteworthy, as these elements are integral to the incorporation of CEAs into health policy. Another important area for investigation is identifying how the QHES should evolve to reflect more contemporary standards for health economic evaluations, such as updates proposed by Second Panel on Cost-Effectiveness in Health and Medicine. In addition, we were concerned that private funding could influence the quality and/or results of health economic evaluations and therefore collected data on funding sources. However, in our analyses, private funding was not significantly associated with study quality. While this finding was reassuring, we believe that other domains should be investigated for association (e.g., is funding source associated with the magnitude of the cost-effectiveness ratio or the rigor of assumptions incorporated in a cost-effectiveness).
Our analysis had several limitations. First, our study focused exclusively on the cardiovascular RCTs included in the ACC/AHA 2012 guideline on ischemic heart disease, and this may have led to the exclusion of relevant, non-RCT based economic evaluations. Specifically, our search strategy may not have identified economic evaluations-particularly model-based economic studies-of treatments for patients with stable ischemic heart disease if the authors (or trial name) were not closely linked. However, economic evaluations that are closely linked to RCTs may represent the highest level of economic evidence. Second, it may be argued that the QHES is not an adequate surrogate for a detailed clinical and methodologic review of quality performed by experts. Assigning a numeric value to an ultimately subjective assessment is potentially erroneous. With its checklist approach to evaluating the criterion of study quality, the QHES does not capture the more complex • Markov model with clinical
• High validity because health
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• High validity because most parameters
• High degree of technical rigor in
• Markov models are a widely aspects of study quality such as appropriateness of modeling approach, choice of model inputs, or analytic rigor. However, we believe some degree of standardization when reviewing study quality is necessary, and there is support for the face validity, content validity, construct validity, criterion validity, and reliability of the QHES, at least as a "first pass" instrument for review of an economic evaluation. 9 Third, the relatively small number of economic evaluations we reviewed limited the statistical analyses that could be performed. In addition, † Assumption of equal hazard rates in post-trial period between intervention and control group is a commonly used, conservative assumption but likely less accurate than carrying hazard ratio forward if intervention effects continue in post-trial period. This could substantially influence cost-effectiveness ratio. ‡ Probability of death in intervention group at 1,000 days was 0.048 compared to 0.030 in control group (p=0.31). By assuming equal death rates, as the authors did, uncertainty in the death rate estimates is not reflected in the cost-effectiveness analysis. The assumption also favors the intervention group, which increases the intervention's economic value. § Survival of patients in clinical trial was projected using age-and sex-specific estimates from Framingham Heart Study, the Saskatchewan Health database, and the Worcester Heart Attack Registry.
our PubMed search extended from inception to 2015 but may not reflect a contemporary sample of economic evaluations, particularly since we found that quality has improved over time. One implication of this is that guideline developers could consider relying more heavily on more contemporary economic evaluations when possible.
In conclusion, the economic evaluations of RCTs cited in the ACC/AHA 2012 guidelines were generally of high quality, and quality has improved over time. However, a substantial proportion of studies were low quality, and studies did not consistently report patient characteristics or address statistical and clinical uncertainty. In addition, a detailed assessment of a random subset of studies revealed that methodological issues existed among "highquality" studies that were unaddressed by the QHES. Because the ACC/AHA has generally been more systematic in its integration of scientific evidence compared to other professional societies, it is likely that most professional societies will need to proceed more cautiously in their integration of economic evidence into clinical practice guidelines in order to reduce the risk of mischaracterizing the value of medical treatments. 
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